<DOC>
	<DOC>NCT02104336</DOC>
	<brief_summary>Treatment of Pediatric Subjects with Pearson syndrome</brief_summary>
	<brief_title>Phase 2 Study of EPI-743 in Children With Pearson Syndrome</brief_title>
	<detailed_description>If effective, treatment with EPI-743 should result in a significant reduction in occurrence of sepsis, metabolic crisis, hepatic failure and transfusion dependence.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lipid Metabolism, Inborn Errors</mesh_term>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Genetically confirmed diagnosis of Pearson syndrome Age less than 18 Availability of medical history for 12 months prior to enrollment Abstention from use of CoQ10, vitamin E, lipoic acid and Idebenone 14 days prior to treatment with EPI743 Allergy to EPI743, sesame oil or vitamin E Clinical history of bleeding/ abnormal PT/PTT Concurrent inborn errors of metabolism Use of anticoagulant medications Participation in any interventional study within 30 days of treatment Use of erythropoietin 30 days prior to trial enrollment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Pearson</keyword>
	<keyword>EPI743</keyword>
	<keyword>EPI-743</keyword>
	<keyword>Vincerinone</keyword>
	<keyword>Mitochondrial disorder</keyword>
	<keyword>Mitochondrial disease</keyword>
</DOC>